 TORONTO, ON ACCESSWIRE June 15, 2020 Edesa Biotech, Inc. EDSA, a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 23 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to accelerate the initiation and rollout of the study, beginning at up to 30 sites. Based on previous clinical data and the mechanism of action, the company believes that modulating this well understood signaling pathway could reduce the number of ICU patients and intubationventilation procedures, ultimately saving lives. 